NAVLE Hemic and lymphic

Canine Bone Marrow Disease Study Guide

📅 March 28, 2026 ⏱ 25 min read 👁 5 views
Bone marrow diseases represent a critically important category of hematologic disorders in veterinary medicine.

Overview and Clinical Importance

Bone marrow diseases represent a critically important category of hematologic disorders in veterinary medicine. These conditions encompass a spectrum of disorders ranging from pancytopenia (simultaneous reduction of all blood cell lines) to neoplastic conditions such as multiple myeloma (a plasma cell neoplasm). Understanding the pathophysiology, diagnosis, and management of these conditions is essential for the NAVLE examination and clinical practice.

Bone marrow evaluation is the diagnostic cornerstone for these disorders, as peripheral blood findings alone are often insufficient for definitive diagnosis. The ability to distinguish between infectious, immune-mediated, neoplastic, and idiopathic causes of bone marrow failure directly impacts treatment decisions and prognosis.

Parameter Threshold Value Clinical Significance
Packed Cell Volume (PCV) Less than 36% Indicates anemia; nonregenerative in bone marrow disease
Total WBC Count Less than 6,000/μL Leukopenia; neutropenia is most clinically significant
Segmented Neutrophils Less than 3,000/μL Increases susceptibility to infection
Platelet Count Less than 200,000/μL Thrombocytopenia; risk of spontaneous bleeding below 30,000/μL

Pancytopenia

Definition and Pathophysiology

Pancytopenia is defined as the simultaneous reduction of all three major blood cell lines: red blood cells (anemia), white blood cells (leukopenia), and platelets (thrombocytopenia). This condition results from either decreased bone marrow production (hypoproliferative causes) or increased peripheral destruction/consumption of blood cells.

High-YieldWhen evaluating pancytopenia, always consider the temporal progression: granulocytes are affected first (shortest lifespan of 6-8 hours), followed by platelets (lifespan of 5-7 days), and finally red blood cells (lifespan of 100-120 days in dogs). This explains why neutropenia often precedes anemia in acute bone marrow failure.

Diagnostic Criteria for Canine Pancytopenia

Causes of Canine Pancytopenia

Infectious Causes

Ehrlichia canis (Canine Monocytic Ehrlichiosis): This is one of the most common infectious causes of pancytopenia in dogs, particularly in endemic areas. The chronic phase of ehrlichiosis is characterized by severe aplastic pancytopenia with bone marrow hypoplasia. German Shepherd Dogs appear predisposed to severe manifestations. Clinical signs include lethargy, weight loss, bleeding diathesis (petechiae, ecchymoses, epistaxis), lymphadenomegaly, and splenomegaly. Diagnosis requires serology (IFA titers), PCR, and bone marrow evaluation. Treatment with doxycycline (10 mg/kg PO q24h for 28 days) is the standard, though prognosis is guarded in chronic cases with severe bone marrow aplasia.

Canine Parvovirus: Although primarily causing gastrointestinal disease in puppies, parvovirus directly infects rapidly dividing bone marrow precursor cells, leading to transient pancytopenia. The neutropenia is particularly significant as it predisposes to secondary bacterial sepsis, which is often the cause of death.

Drug-Induced Causes

Chemotherapeutic agents, particularly doxorubicin, are the most common drug-related cause of pancytopenia. Other medications associated with bone marrow suppression include estrogens (from Sertoli cell tumors or exogenous administration), NSAIDs (particularly phenylbutazone), antimicrobials (chloramphenicol, trimethoprim-sulfa), anticonvulsants, and antithyroid medications (methimazole).

NAVLE TipEstrogen toxicity from Sertoli cell tumors is a classic board question. Remember that estrogen causes bone marrow suppression by inhibiting hematopoietic stem cells. The myelotoxicity is often irreversible, and prognosis is poor once pancytopenia develops.

Neoplastic Causes

Myelophthisis refers to the replacement of normal bone marrow elements by neoplastic cells, leading to decreased production of all blood cell lines. Common neoplastic causes include:

  • Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)
  • Multiple myeloma (plasma cell neoplasm)
  • Malignant histiocytosis (particularly in Bernese Mountain Dogs, Rottweilers, and Golden Retrievers)
  • Lymphoma with bone marrow infiltration
  • Metastatic carcinoma

Other Causes

Category Examples and Key Points
Idiopathic Aplastic Anemia Suspected immune-mediated destruction of hematopoietic stem cells. Bone marrow shows hypocellularity with adipocyte replacement. Mortality rate of 66-80% despite treatment.
Myelodysplastic Syndrome Clonal disorder characterized by ineffective hematopoiesis and dysplastic changes. Often progresses to acute myeloid leukemia.
Myelofibrosis Replacement of bone marrow with fibrous tissue. Primary or secondary to other marrow disorders. Core biopsy required for diagnosis.
Hemophagocytic Syndrome Macrophages phagocytose blood cell precursors. Often associated with systemic inflammatory conditions.
Bone Marrow Necrosis Can occur secondary to sepsis, drug toxicity, or neoplasia. Often concurrent with DIC.

Multiple Myeloma

Definition and Pathophysiology

Multiple myeloma is a malignant neoplasm arising from terminally differentiated B lymphocytes (plasma cells) in the bone marrow. These neoplastic plasma cells produce excessive amounts of a single immunoglobulin class or immunoglobulin component, termed a paraprotein or M-component. Multiple myeloma accounts for less than 8% of all hematopoietic tumors in dogs and is rare in cats. There is no breed or sex predisposition, and older dogs (mean age 8-9 years) are most commonly affected.

The pathologic conditions associated with multiple myeloma result from two main mechanisms: (1) effects of the circulating paraprotein including hyperviscosity syndrome and bleeding diathesis, and (2) organ or bone marrow dysfunction due to neoplastic infiltration including cytopenias, osteolysis, hypercalcemia, renal disease, and increased susceptibility to infection.

High-YieldIgG and IgA gammopathies are equally common in dogs, while cats develop predominantly IgG (80%) and IgA (20%) gammopathies. IgM gammopathy (Waldenstrom's macroglobulinemia) is rare but causes more severe hyperviscosity syndrome due to the large molecular size of IgM pentamers.

Diagnostic Criteria

Diagnosis of multiple myeloma requires demonstration of at least two of the following four criteria:

Clinical Presentation

Diagnostic Workup

A thorough diagnostic workup for suspected multiple myeloma should include:

  • Complete Blood Count (CBC): Normocytic, normochromic, nonregenerative anemia in two-thirds of patients. Pancytopenia may be present with severe marrow infiltration.
  • Serum Biochemistry: Hyperglobulinemia, hypercalcemia (15-20% of dogs), azotemia, hypoalbuminemia.
  • Serum Protein Electrophoresis (SPE): Monoclonal spike in beta or gamma region. Immunofixation can identify the specific immunoglobulin class.
  • Urinalysis and Urine Protein Electrophoresis: Detection of Bence Jones proteins (light chains). Standard dipstick is inadequate.
  • Bone Marrow Aspirate and Biopsy: Plasmacytosis (greater than 20% plasma cells). Assess for morphologic atypia.
  • Skeletal Survey Radiographs: Evaluate axial skeleton and long bones for osteolytic lesions. CT may be more sensitive.
  • Serum Viscosity: If hyperviscosity syndrome suspected. Normal is 1.4-1.8 relative to water.

Treatment

Prognosis

Multiple myeloma is not considered curable but is one of the more treatable hematologic malignancies in dogs. With melphalan and prednisone treatment, 92% of dogs experience remission with a median survival time of 540 days (approximately 18 months). However, relapse is expected, and eventual progression is typical.

Negative Prognostic Factors: Extensive osteolytic bone lesions with pathologic fractures, severe anemia, light chain (Bence Jones) proteinuria, azotemia, hypercalcemia, and poor initial response to treatment.

NAVLE TipRemember that multiple myeloma cells are quite sensitive to radiation therapy, which can be used palliatively for localized painful bone lesions. However, radiation does not replace systemic chemotherapy for controlling the underlying disease.
Criterion Diagnostic Finding Key Points
1. Bone Marrow Plasmacytosis Greater than 20% plasma cells in bone marrow aspirate or biopsy Plasma cells show eccentric nucleus, basophilic cytoplasm, and perinuclear clear zone (Golgi)
2. Monoclonal Gammopathy Tall, narrow spike in beta or gamma region on serum protein electrophoresis IgG or IgA most common; uninvolved immunoglobulins typically decreased
3. Osteolytic Lesions Multiple punched-out lytic lesions or diffuse osteopenia on radiographs Common in vertebrae, ribs, pelvis, skull, and long bones; present in 25-50% of dogs
4. Bence Jones Proteinuria Light chains (kappa or lambda) detected in urine by electrophoresis Present in 25-40% of dogs; standard dipstick does NOT detect Bence Jones proteins

Myelodysplastic Syndromes

Myelodysplastic syndromes (MDS) are a heterogeneous group of acquired clonal hematologic disorders characterized by ineffective hematopoiesis, resulting in peripheral blood cytopenias despite hypercellular or normocellular bone marrow. Dysplastic morphologic changes are present in one or more cell lines.

MDS can be primary (spontaneous) or secondary (following exposure to chemotherapeutic agents, radiation, or toxins). A significant concern is that MDS can progress to acute myeloid leukemia (AML), defined by greater than 20-30% blast cells in bone marrow. The prognosis for primary MDS is generally poor, with many dogs dying or being euthanized within weeks to months of diagnosis.

Exam Focus: Key cytologic features of dysplasia include: (1) Dyserythropoiesis - nuclear abnormalities, megaloblastic changes; (2) Dysgranulopoiesis - hypersegmented or hyposegmented nuclei, giant bands, pseudo-Pelger-Huet anomaly; (3) Dysmegakaryopoiesis - micromegakaryocytes, abnormal nuclear lobulation.

Clinical Sign Frequency Pathophysiology
Lethargy/Weakness 62% Anemia, hypercalcemia, hyperviscosity
Lameness/Bone Pain 47% Osteolytic lesions, pathologic fractures
Bleeding Diathesis 37% Paraprotein interferes with platelet function and coagulation factors
Ophthalmic Problems 35% Hyperviscosity causes retinal hemorrhage, vessel tortuosity, detachment
PU/PD 25% Hypercalcemia, renal damage from Bence Jones proteinuria
Neurologic Signs 12% Hyperviscosity, hypercalcemia, spinal cord compression from vertebral lesions

Bone Marrow Evaluation

Indications for Bone Marrow Sampling

  • Unexplained bicytopenia or pancytopenia
  • Nonregenerative anemia after extra-marrow causes excluded
  • Unexplained neutropenia or thrombocytopenia
  • Circulating blast cells or atypical cells on blood smear
  • Staging of neoplasia (lymphoma, mast cell tumor)
  • Hyperglobulinemia with suspected myeloma
  • Fever of unknown origin with hematologic abnormalities

Sample Collection Sites

The most commonly used sites are the proximal humerus and iliac crest in adult dogs. General anesthesia is recommended. Both aspirate (for cytology) and core biopsy (for histopathology) should ideally be collected concurrently, as they provide complementary information.

Interpretation of Bone Marrow Cytology

Treatment Protocol Notes
First-Line Chemotherapy Melphalan (0.1 mg/kg PO daily for 10 days, then 0.05 mg/kg daily) + Prednisone (0.5 mg/kg PO daily) 92% response rate; monitor CBC q2-4 weeks for myelosuppression. Discontinue prednisone after 60 days.
Alternative Protocol Melphalan 7 mg/m² PO once daily for 5 consecutive days every 3 weeks Similar efficacy to daily dosing; may have better compliance
Hyperviscosity Syndrome Plasmapheresis for acute management; IV fluid diuresis Emergency treatment if severe neurologic or ophthalmic signs
Hypercalcemia IV saline diuresis, furosemide, bisphosphonates (pamidronate or zoledronic acid) Bisphosphonates also help reduce osteolysis and bone pain
Pain Management NSAIDs (if renal function adequate), gabapentin, opioids Radiation therapy for localized painful lesions
Parameter Normal Value Clinical Significance
Cellularity 50-75% hematopoietic cells; decreases with age Hypocellular in aplastic anemia; hypercellular in leukemia
M:E Ratio 0.75-2.5:1 in dogs Increased with erythroid hypoplasia or myeloid hyperplasia; decreased with erythroid hyperplasia
Blast Cells Less than 3% of nucleated cells Greater than 20% suggests acute leukemia; 5-20% suggests MDS
Plasma Cells Less than 5% Greater than 20% supports multiple myeloma diagnosis
Megakaryocytes 5-10 per low-power field Decreased in aplastic conditions; increased in IMT or chronic blood loss

Practice NAVLE Questions

Test your knowledge with 10,000+ exam-style questions, detailed explanations, and timed exams.

Start Your Free Trial →

Related Articles

NAVLE

Canine Coagulopathy Study Guide

 NAVLE

Canine Anemia (General) Study Guide